<p>随着澳大利亚市场在商品价格稳定和华尔街强劲表现的推动下，预计本周将以积极的态势收尾，投资者正在关注各个领域的机会。尽管 “便士股票” 这一名称有些过时，但对于那些寻求小型或新兴公司潜在价值和增长的投资者来说，仍然是一个引人注目的领域。这些股票在稳健的财务基础上，结合资产负债表的强劲表现，能够提供可观的回报。</p>
<h3>澳大利亚十大便士股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>股价</strong></td>
<td><strong>市值</strong></td>
<td><strong>回报与风险</strong></td>
</tr>
<tr>
<td>Alfabs Australia (ASX:AAL)</td>
<td>A$0.47</td>
<td>A$134.7M</td>
<td>✅ 4 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>EZZ Life Science Holdings (ASX:EZZ)</td>
<td>A$2.19</td>
<td>A$103.31M</td>
<td>✅ 3 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Dusk Group (ASX:DSK)</td>
<td>A$0.85</td>
<td>A$52.93M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>IVE Group (ASX:IGL)</td>
<td>A$2.80</td>
<td>A$432.95M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>MotorCycle Holdings (ASX:MTO)</td>
<td>A$3.73</td>
<td>A$275.3M</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Veris (ASX:VRS)</td>
<td>A$0.0745</td>
<td>A$38.57M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>SHAPE Australia (ASX:SHA)</td>
<td>A$4.34</td>
<td>A$357.38M</td>
<td>✅ 3 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>West African Resources (ASX:WAF)</td>
<td>A$3.04</td>
<td>A$3.47B</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Tasmea (ASX:TEA)</td>
<td>A$4.43</td>
<td>A$1.08B</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Praemium (ASX:PPS)</td>
<td>A$0.79</td>
<td>A$377.78M</td>
<td>✅ 5 ⚠️ 2 查看分析</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们 ASX 便士股票筛选器中的 441 只股票的完整列表。</p>
<p>让我们更仔细地看看我们从筛选公司中挑选的几只股票。</p>
<h2>BKI Investment (ASX:BKI)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> BKI Investment Company Limited 是一家公开上市的投资管理公司，市值为 14.6 亿澳元。</p>
<p><strong>运营：</strong> BKI Investment 的收入完全来自证券行业，金额为 6933 万澳元。</p>
<p><strong>市值：</strong> A$1.46B</p>
<p>BKI Investment Company Limited 市值为 14.6 亿澳元，凭借无债务状态和高质量收益展现出财务稳定性。尽管来自证券行业的收入稳定为 6933 万澳元，但公司最近的财报显示净收入较去年略有下降，降至 6186 万澳元。尽管股息收益率仍具吸引力，达到 4.35%，但未能完全由收益或自由现金流覆盖，这引发了可持续性担忧。最近的董事会变动包括亚历山大·佩恩先生新被认定为独立董事，可能增强 BKI 成熟董事会结构内的治理动态。</p>
<ul>
<li>在这里深入了解 BKI Investment 的具体情况，查看我们的详细资产负债表健康报告。</li>
<li>通过我们的详细历史业绩报告评估 BKI Investment 的过去业绩。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ce30ff96-4907-433a-8e72-16c855a12dcf/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ce30ff96-4907-433a-8e72-16c855a12dcf/chart/financial-position-analysis"/></p>
<p>截至 2025 年 9 月的 ASX:BKI 财务状况分析</p>
<h2>Dimerix (ASX:DXB)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★★</p>
<p><strong>概述：</strong> Dimerix Limited 是一家生物制药公司，专注于开发和商业化满足澳大利亚未满足医疗需求的药品，市值为 2.8809 亿澳元。</p>
<p><strong>运营：</strong> 公司的收入完全来自职业药物检测设备和新治疗剂的开发，金额为 559 万澳元。</p>
<p><strong>市值：</strong> A$288.09M</p>
<p>Dimerix Limited 市值为 2.8809 亿澳元，尽管报告了截至 2025 年 6 月 30 日的销售额为 559 万澳元，但仍处于无收入状态。公司处于亏损状态，净亏损为 1325 万澳元，但由于自由现金流为正，其现金流持续超过三年。Dimerix 的管理层和董事会经验丰富，平均任期分别为 4.3 年和 7.9 年，这可能有助于在行业挑战中提供战略方向。该股票的交易价格显著低于估计的公允价值，并且无债务，短期资产大幅超过负债。</p>
<ul>
<li>在这里深入了解 Dimerix 的完整分析健康报告。</li>
<li>通过查看我们的业绩历史报告了解 Dimerix 的业绩记录。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2af6f193-a47c-4ab6-a34a-c1f1aabe8db6/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2af6f193-a47c-4ab6-a34a-c1f1aabe8db6/chart/revenue-and-expenses-breakdown"/></p>
<p>截至 2025 年 9 月的 ASX:DXB 收入与支出明细</p>
<h2>Kingsgate Consolidated (ASX:KCN)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Kingsgate Consolidated Limited 从事黄金和白银矿产的勘探、开发和开采，市值为 7.6712 亿澳元。</p>
<p><strong>运营：</strong> 公司的收入主要来自其 Chatree 部门，产生了 3.3675 亿澳元的收入。</p>
<p><strong>市值：</strong> A$767.12M</p>
<p>Kingsgate Consolidated Limited 市值为 7.6712 亿澳元，报告了来自其 Chatree 部门的显著收入增长，达到截至 2025 年 6 月 30 日的 3.3675 亿澳元。然而，净收入从去年的 1.9976 亿澳元下降至 2946 万澳元，原因是利润率和每股收益下降。公司在五年内成功降低了其债务与股本比率，并保持相对满意的净债务水平。尽管每周波动稳定且过去收益质量高，但当前的利息覆盖率仍低于最佳水平，表明在有效管理财务义务方面可能面临挑战。</p>
<ul>
<li>在我们的财务健康报告中更仔细地了解 Kingsgate Consolidated 的潜力。</li>
<li>通过访问我们的收益增长报告评估 Kingsgate Consolidated 的前景。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6ebaac19-4401-459e-b09a-25df53b825b0/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6ebaac19-4401-459e-b09a-25df53b825b0/chart/debt-equity-history-analysis"/></p>
<p>截至 2025 年 9 月的 ASX:KCN 债务与股本历史及分析</p>
<h2>关键要点</h2>
<ul>
<li>点击这里访问我们完整的 441 只 ASX 便士股票指数。</li>
<li>对其他可能性感兴趣？我们发现 17 只美国股票预计明年将支付超过 6% 的股息收益率。查看完整列表，免费获取。</li>
</ul>
<p><em>这篇文章来自 Simply Wall St，内容具有一般性。<strong>我们基于历史数据和分析师预测提供评论，仅使用无偏见的方法，我们的文章不构成财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>

<p>BKI 投资和另外两只 ASX 便士股票被认为是在积极的市场前景下的潜在投资机会。BKI 投资公司（BKI Investment Company Limited）市值为 14.6 亿澳元，显示出财务稳定性，但对其股息可持续性存在担忧。Dimerix Limited 是一家生物制药公司，尚未产生收入，但拥有稳定的现金流。Kingsgate Consolidated Limited 专注于黄金和白银开采，报告了收入增长，但净收入下降。投资者被鼓励探索这些股票以寻找潜在的价值和增长</p>

<p>As the Australian market looks to end the week on a positive note, buoyed by steady commodities and a strong overnight performance on Wall Street, investors are eyeing opportunities in various segments. Penny stocks, despite their somewhat outdated name, remain an intriguing area for those seeking potential value and growth in smaller or newer companies. With solid financial foundations, these stocks can offer promising returns as they combine balance sheet strength with potential for significant gains.</p>
<div class="lb-trans"><p>随着澳大利亚市场在商品价格稳定和华尔街强劲表现的推动下，预计本周将以积极的态势收尾，投资者正在关注各个领域的机会。尽管 “便士股票” 这一名称有些过时，但对于那些寻求小型或新兴公司潜在价值和增长的投资者来说，仍然是一个引人注目的领域。这些股票在稳健的财务基础上，结合资产负债表的强劲表现，能够提供可观的回报。</p>
</div><h3>Top 10 Penny Stocks In Australia</h3>
<div class="lb-trans"><h3>澳大利亚十大便士股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Share Price</strong></td>
<td><strong>Market Cap</strong></td>
<td><strong>Rewards &amp; Risks</strong></td>
</tr>
<tr>
<td>Alfabs Australia (ASX:AAL)</td>
<td>A$0.47</td>
<td>A$134.7M</td>
<td>✅ 4 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>EZZ Life Science Holdings (ASX:EZZ)</td>
<td>A$2.19</td>
<td>A$103.31M</td>
<td>✅ 3 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>Dusk Group (ASX:DSK)</td>
<td>A$0.85</td>
<td>A$52.93M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>IVE Group (ASX:IGL)</td>
<td>A$2.80</td>
<td>A$432.95M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>MotorCycle Holdings (ASX:MTO)</td>
<td>A$3.73</td>
<td>A$275.3M</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Veris (ASX:VRS)</td>
<td>A$0.0745</td>
<td>A$38.57M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>SHAPE Australia (ASX:SHA)</td>
<td>A$4.34</td>
<td>A$357.38M</td>
<td>✅ 3 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>West African Resources (ASX:WAF)</td>
<td>A$3.04</td>
<td>A$3.47B</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Tasmea (ASX:TEA)</td>
<td>A$4.43</td>
<td>A$1.08B</td>
<td>✅ 3 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Praemium (ASX:PPS)</td>
<td>A$0.79</td>
<td>A$377.78M</td>
<td>✅ 5 ⚠️ 2 View Analysis &gt;</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>股价</strong></td>
<td><strong>市值</strong></td>
<td><strong>回报与风险</strong></td>
</tr>
<tr>
<td>Alfabs Australia (ASX:AAL)</td>
<td>A$0.47</td>
<td>A$134.7M</td>
<td>✅ 4 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>EZZ Life Science Holdings (ASX:EZZ)</td>
<td>A$2.19</td>
<td>A$103.31M</td>
<td>✅ 3 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Dusk Group (ASX:DSK)</td>
<td>A$0.85</td>
<td>A$52.93M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>IVE Group (ASX:IGL)</td>
<td>A$2.80</td>
<td>A$432.95M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>MotorCycle Holdings (ASX:MTO)</td>
<td>A$3.73</td>
<td>A$275.3M</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Veris (ASX:VRS)</td>
<td>A$0.0745</td>
<td>A$38.57M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>SHAPE Australia (ASX:SHA)</td>
<td>A$4.34</td>
<td>A$357.38M</td>
<td>✅ 3 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>West African Resources (ASX:WAF)</td>
<td>A$3.04</td>
<td>A$3.47B</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Tasmea (ASX:TEA)</td>
<td>A$4.43</td>
<td>A$1.08B</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Praemium (ASX:PPS)</td>
<td>A$0.79</td>
<td>A$377.78M</td>
<td>✅ 5 ⚠️ 2 查看分析</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 441 stocks from our ASX Penny Stocks screener.</p>
<div class="lb-trans"><p>点击这里查看我们 ASX 便士股票筛选器中的 441 只股票的完整列表。</p>
</div><p>Let's take a closer look at a couple of our picks from the screened companies.</p>
<div class="lb-trans"><p>让我们更仔细地看看我们从筛选公司中挑选的几只股票。</p>
</div><h2>BKI Investment (ASX:BKI)</h2>
<div class="lb-trans"><h2>BKI Investment (ASX:BKI)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> BKI Investment Company Limited is a publicly owned investment manager with a market cap of A$1.46 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> BKI Investment Company Limited 是一家公开上市的投资管理公司，市值为 14.6 亿澳元。</p>
</div><p><strong>Operations:</strong> BKI Investment's revenue is derived entirely from the Securities Industry, amounting to A$69.33 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> BKI Investment 的收入完全来自证券行业，金额为 6933 万澳元。</p>
</div><p><strong>Market Cap:</strong> A$1.46B</p>
<div class="lb-trans"><p><strong>市值：</strong> A$1.46B</p>
</div><p>BKI Investment Company Limited, with a market cap of A$1.46 billion, demonstrates financial stability through its debt-free status and high-quality earnings. Despite a steady revenue stream of A$69.33 million from the securities industry, the company's recent earnings report shows a slight decline in net income to A$61.86 million from last year. The dividend yield remains attractive at 4.35%, although it is not fully covered by earnings or free cash flows, raising sustainability concerns. Recent board changes include Mr. Alexander Payne's newly recognized independence as a director, potentially enhancing governance dynamics within BKI's seasoned board structure.</p>
<div class="lb-trans"><p>BKI Investment Company Limited 市值为 14.6 亿澳元，凭借无债务状态和高质量收益展现出财务稳定性。尽管来自证券行业的收入稳定为 6933 万澳元，但公司最近的财报显示净收入较去年略有下降，降至 6186 万澳元。尽管股息收益率仍具吸引力，达到 4.35%，但未能完全由收益或自由现金流覆盖，这引发了可持续性担忧。最近的董事会变动包括亚历山大·佩恩先生新被认定为独立董事，可能增强 BKI 成熟董事会结构内的治理动态。</p>
</div><ul>
<li>Dive into the specifics of BKI Investment here with our thorough balance sheet health report.</li>
<li>Assess BKI Investment's previous results with our detailed historical performance reports.</li>
</ul>
<div class="lb-trans"><ul>
<li>在这里深入了解 BKI Investment 的具体情况，查看我们的详细资产负债表健康报告。</li>
<li>通过我们的详细历史业绩报告评估 BKI Investment 的过去业绩。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ce30ff96-4907-433a-8e72-16c855a12dcf/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/ce30ff96-4907-433a-8e72-16c855a12dcf/chart/financial-position-analysis"/></p>
<p>ASX:BKI Financial Position Analysis as at Sep 2025</p>
<div class="lb-trans"><p>截至 2025 年 9 月的 ASX:BKI 财务状况分析</p>
</div><h2>Dimerix (ASX:DXB)</h2>
<div class="lb-trans"><h2>Dimerix (ASX:DXB)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Dimerix Limited is a biopharmaceutical company focused on developing and commercializing pharmaceutical products for unmet medical needs in Australia, with a market cap of A$288.09 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Dimerix Limited 是一家生物制药公司，专注于开发和商业化满足澳大利亚未满足医疗需求的药品，市值为 2.8809 亿澳元。</p>
</div><p><strong>Operations:</strong> The company's revenue is derived entirely from the development of occupational drug testing devices and new therapeutic agents, amounting to A$5.59 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司的收入完全来自职业药物检测设备和新治疗剂的开发，金额为 559 万澳元。</p>
</div><p><strong>Market Cap:</strong> A$288.09M</p>
<div class="lb-trans"><p><strong>市值：</strong> A$288.09M</p>
</div><p>Dimerix Limited, with a market cap of A$288.09 million, remains pre-revenue despite reporting sales of A$5.59 million for the year ended June 30, 2025. The company is unprofitable with a net loss of A$13.25 million, though its cash runway is secure for over three years due to positive free cash flow. Dimerix's management and board are experienced, averaging tenures of 4.3 and 7.9 years respectively, which may aid strategic direction amidst industry challenges. The stock trades significantly below estimated fair value and remains debt-free with short-term assets exceeding liabilities by a substantial margin.</p>
<div class="lb-trans"><p>Dimerix Limited 市值为 2.8809 亿澳元，尽管报告了截至 2025 年 6 月 30 日的销售额为 559 万澳元，但仍处于无收入状态。公司处于亏损状态，净亏损为 1325 万澳元，但由于自由现金流为正，其现金流持续超过三年。Dimerix 的管理层和董事会经验丰富，平均任期分别为 4.3 年和 7.9 年，这可能有助于在行业挑战中提供战略方向。该股票的交易价格显著低于估计的公允价值，并且无债务，短期资产大幅超过负债。</p>
</div><ul>
<li>Jump into the full analysis health report here for a deeper understanding of Dimerix.</li>
<li>Understand Dimerix's track record by examining our performance history report.</li>
</ul>
<div class="lb-trans"><ul>
<li>在这里深入了解 Dimerix 的完整分析健康报告。</li>
<li>通过查看我们的业绩历史报告了解 Dimerix 的业绩记录。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2af6f193-a47c-4ab6-a34a-c1f1aabe8db6/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/2af6f193-a47c-4ab6-a34a-c1f1aabe8db6/chart/revenue-and-expenses-breakdown"/></p>
<p>ASX:DXB Revenue &amp; Expenses Breakdown as at Sep 2025</p>
<div class="lb-trans"><p>截至 2025 年 9 月的 ASX:DXB 收入与支出明细</p>
</div><h2>Kingsgate Consolidated (ASX:KCN)</h2>
<div class="lb-trans"><h2>Kingsgate Consolidated (ASX:KCN)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Kingsgate Consolidated Limited is involved in the exploration, development, and mining of gold and silver mineral properties, with a market cap of A$767.12 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Kingsgate Consolidated Limited 从事黄金和白银矿产的勘探、开发和开采，市值为 7.6712 亿澳元。</p>
</div><p><strong>Operations:</strong> The company's revenue is primarily derived from its Chatree segment, which generated A$336.75 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司的收入主要来自其 Chatree 部门，产生了 3.3675 亿澳元的收入。</p>
</div><p><strong>Market Cap:</strong> A$767.12M</p>
<div class="lb-trans"><p><strong>市值：</strong> A$767.12M</p>
</div><p>Kingsgate Consolidated Limited, with a market cap of A$767.12 million, reported significant revenue growth from its Chatree segment, reaching A$336.75 million for the year ended June 30, 2025. However, net income declined to A$29.46 million from the previous year's A$199.76 million due to reduced profit margins and earnings per share. The company has successfully reduced its debt-to-equity ratio over five years and maintains satisfactory net debt levels relative to equity. Despite stable weekly volatility and high-quality past earnings, current interest coverage remains below optimal levels, indicating potential challenges in managing financial obligations effectively.</p>
<div class="lb-trans"><p>Kingsgate Consolidated Limited 市值为 7.6712 亿澳元，报告了来自其 Chatree 部门的显著收入增长，达到截至 2025 年 6 月 30 日的 3.3675 亿澳元。然而，净收入从去年的 1.9976 亿澳元下降至 2946 万澳元，原因是利润率和每股收益下降。公司在五年内成功降低了其债务与股本比率，并保持相对满意的净债务水平。尽管每周波动稳定且过去收益质量高，但当前的利息覆盖率仍低于最佳水平，表明在有效管理财务义务方面可能面临挑战。</p>
</div><ul>
<li>Take a closer look at Kingsgate Consolidated's potential here in our financial health report.</li>
<li>Evaluate Kingsgate Consolidated's prospects by accessing our earnings growth report.</li>
</ul>
<div class="lb-trans"><ul>
<li>在我们的财务健康报告中更仔细地了解 Kingsgate Consolidated 的潜力。</li>
<li>通过访问我们的收益增长报告评估 Kingsgate Consolidated 的前景。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6ebaac19-4401-459e-b09a-25df53b825b0/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/6ebaac19-4401-459e-b09a-25df53b825b0/chart/debt-equity-history-analysis"/></p>
<p>ASX:KCN Debt to Equity History and Analysis as at Sep 2025</p>
<div class="lb-trans"><p>截至 2025 年 9 月的 ASX:KCN 债务与股本历史及分析</p>
</div><h2>Key Takeaways</h2>
<div class="lb-trans"><h2>关键要点</h2>
</div><ul>
<li>Click here to access our complete index of 441 ASX Penny Stocks.</li>
<li>Interested In Other Possibilities? We've found 17 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里访问我们完整的 441 只 ASX 便士股票指数。</li>
<li>对其他可能性感兴趣？我们发现 17 只美国股票预计明年将支付超过 6% 的股息收益率。查看完整列表，免费获取。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇文章来自 Simply Wall St，内容具有一般性。<strong>我们基于历史数据和分析师预测提供评论，仅使用无偏见的方法，我们的文章不构成财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div>

BKI 投资及其他两个 ASX 低价股值得考虑